3 581

Cited 44 times in

LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients.

DC Field Value Language
dc.contributor.author안성귀-
dc.contributor.author이재면-
dc.contributor.author이학민-
dc.contributor.author이희대-
dc.contributor.author정준-
dc.date.accessioned2014-12-18T09:10:23Z-
dc.date.available2014-12-18T09:10:23Z-
dc.date.issued2013-
dc.identifier.issn0167-6806-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/87669-
dc.description.abstractLysyl oxidase-like 2 (LOXL2) is associated with invasiveness and metastasis in breast cancer. We analyzed the prognostic impact of LOXL2 for breast cancer patients and investigated the role of LOXL2 in breast cancer cell lines. Immunohistochemical study of LOXL2 expression was done in samples from 309 patients. Survival analysis was performed using log-rank test and Cox regression hazard model. After identification of LOXL2 expression in breast cancer cell lines, we performed matrigel invasion and wound-healing assays with LOXL2-silenced cell lines. In the human study, LOXL2 was expressed in 16.2 % of patients. Comparing the LOXL2-positive versus negative groups, there was a significantly higher proportion of estrogen receptor-negative patients (54.0 vs. 37.0 %, respectively; p = 0.029) and triple-negative patients (34.0 vs. 18.0 %; p = 0.022) in the positive group. In multivariate analysis for overall survival and metastasis-free survival, positive LOXL2 was demonstrated as a poor prognostic factor (HR 2.27 and 2.10, respectively). In vitro study indicated that LOXL2 silencing induces a mesenchymal–epithelial transition-like process in basal cell lines (MDA-MB-231 and BT549) associated with decreased invasive and migratory properties. These clinical and preclinical data confirm that higher LOXL2 expression is associated with invasiveness of basal-like breast cancer cells and lower survival of breast cancer patients. Our results suggest the clinical value of LOXL2 as a therapeutic target in breast cancer.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfBREAST CANCER RESEARCH AND TREATMENT-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAmino Acid Oxidoreductases/analysis*-
dc.subject.MESHAmino Acid Oxidoreductases/biosynthesis-
dc.subject.MESHAmino Acid Oxidoreductases/genetics-
dc.subject.MESHBreast Neoplasms/chemistry*-
dc.subject.MESHBreast Neoplasms/genetics-
dc.subject.MESHBreast Neoplasms/mortality-
dc.subject.MESHBreast Neoplasms/pathology-
dc.subject.MESHCarcinoma/chemistry*-
dc.subject.MESHCarcinoma/genetics-
dc.subject.MESHCarcinoma/mortality-
dc.subject.MESHCarcinoma/pathology-
dc.subject.MESHCarcinoma in Situ/chemistry-
dc.subject.MESHCarcinoma in Situ/genetics-
dc.subject.MESHCarcinoma in Situ/mortality-
dc.subject.MESHCarcinoma in Situ/pathology-
dc.subject.MESHCell Line, Tumor-
dc.subject.MESHCell Movement-
dc.subject.MESHCollagen-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHDrug Combinations-
dc.subject.MESHEpithelial-Mesenchymal Transition-
dc.subject.MESHFemale-
dc.subject.MESHGene Expression Regulation, Neoplastic*-
dc.subject.MESHHumans-
dc.subject.MESHIn Situ Hybridization-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHLaminin-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoadjuvant Therapy-
dc.subject.MESHNeoplasm Invasiveness-
dc.subject.MESHNeoplasm Metastasis-
dc.subject.MESHNeoplasm Proteins/analysis*-
dc.subject.MESHNeoplasm Proteins/biosynthesis-
dc.subject.MESHNeoplasm Proteins/genetics-
dc.subject.MESHNeoplasms, Multiple Primary/chemistry-
dc.subject.MESHNeoplasms, Multiple Primary/genetics-
dc.subject.MESHNeoplasms, Multiple Primary/mortality-
dc.subject.MESHNeoplasms, Multiple Primary/pathology-
dc.subject.MESHPhyllodes Tumor/chemistry-
dc.subject.MESHPhyllodes Tumor/genetics-
dc.subject.MESHPhyllodes Tumor/mortality-
dc.subject.MESHPhyllodes Tumor/pathology-
dc.subject.MESHPrognosis-
dc.subject.MESHProportional Hazards Models-
dc.subject.MESHProteoglycans-
dc.subject.MESHRNA Interference-
dc.subject.MESHRNA, Small Interfering/pharmacology-
dc.subject.MESHSurvival Analysis-
dc.subject.MESHTissue Array Analysis-
dc.subject.MESHTriple Negative Breast Neoplasms/chemistry-
dc.subject.MESHTriple Negative Breast Neoplasms/genetics-
dc.subject.MESHTriple Negative Breast Neoplasms/mortality-
dc.subject.MESHTriple Negative Breast Neoplasms/pathology-
dc.titleLOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Microbiology (미생물학)-
dc.contributor.googleauthorSung Gwe Ahn-
dc.contributor.googleauthorSeung Myung Dong-
dc.contributor.googleauthorAkira Oshima-
dc.contributor.googleauthorWoo Ho Kim-
dc.contributor.googleauthorHak Min Lee-
dc.contributor.googleauthorSeung Ah Lee-
dc.contributor.googleauthorSeung-hyun Kwon-
dc.contributor.googleauthorJi-hae Lee-
dc.contributor.googleauthorJae Myun Lee-
dc.contributor.googleauthorJoon Jeong-
dc.contributor.googleauthorHy-De Lee-
dc.contributor.googleauthorJeffrey E. Green-
dc.identifier.doi10.1007/s10549-013-2662-3-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02231-
dc.contributor.localIdA03071-
dc.contributor.localIdA03272-
dc.contributor.localIdA03347-
dc.contributor.localIdA03727-
dc.relation.journalcodeJ00403-
dc.identifier.eissn1573-7217-
dc.identifier.pmid23933800-
dc.identifier.urlhttp://link.springer.com/article/10.1007%2Fs10549-013-2662-3-
dc.subject.keywordBreast cancer-
dc.subject.keywordLOXL2-
dc.subject.keywordInvasiveness-
dc.subject.keywordTriple negative-
dc.contributor.alternativeNameAhn, Sung Gwe-
dc.contributor.alternativeNameLee, Jae Myun-
dc.contributor.alternativeNameLee, Hak Min-
dc.contributor.alternativeNameLee, Hy De-
dc.contributor.alternativeNameJeong, Joon-
dc.contributor.affiliatedAuthorAhn, Sung Gwe-
dc.contributor.affiliatedAuthorLee, Jae Myun-
dc.contributor.affiliatedAuthorLee, Hak Min-
dc.contributor.affiliatedAuthorLee, Hy De-
dc.contributor.affiliatedAuthorJeong, Joon-
dc.rights.accessRightsnot free-
dc.citation.volume141-
dc.citation.number1-
dc.citation.startPage89-
dc.citation.endPage99-
dc.identifier.bibliographicCitationBREAST CANCER RESEARCH AND TREATMENT, Vol.141(1) : 89-99, 2013-
dc.identifier.rimsid32197-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Microbiology (미생물학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.